<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00718380</url>
  </required_header>
  <id_info>
    <org_study_id>M10-227</org_study_id>
    <nct_id>NCT00718380</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of ABT-869 in Subjects With Solid Tumors</brief_title>
  <official_title>An Open Label, Phase I Study Evaluating Pharmacokinetics, Safety, and Tolerability of ABT-869 in Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the pharmacokinetics, safety and tolerability of
      ABT-869 in Japanese patients with solid tumors up to the Recommended Phase Two Dose that was
      determined in a previous the M04-710 study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety tolerability assessment</measure>
    <time_frame>Weekly assessment for 3 weeks then every 3 weeks or more frequently as needed</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose limiting toxicity determination</measure>
    <time_frame>Weekly assessment for the first 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile evaluation</measure>
    <time_frame>Day 1 and Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary tumor response</measure>
    <time_frame>Every 6 week</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation from Open label 0.05 to 0.25 mg/kg once a day dosing for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label 0.10 mg/kg once a day dosing after safety evolution of Group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label 0.20 mg/kg once a day dosing after safety evolution of Group 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label 0.25 mg/kg once a day dosing after safety evolution of Group 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-869</intervention_name>
    <description>2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Subjects aged from 20 to 75 years and ECOG PS of 0-2 at screening.

          -  Subject must have a solid tumor that is refractory to standard therapies or for which
             a standard effective therapy does not exist.

          -  The subject must have adequate bone marrow, renal and hepatic function.

          -  Women of child-bearing potential and men must agree to use adequate contraception
             prior to study entry, for the duration of study participation and up to six months
             following completion of therapy.

          -  The subject must voluntarily sign and date an informed consent.

        Exclusion Criteria

          -  The subject currently exhibits symptomatic or intervention indicated CNS metastasis.

          -  The subject has received any anti-cancer therapy including chemotherapy,
             immunotherapy, radiotherapy, hormonal, biologic or any investigational therapy within
             4 weeks of enrollment or has not fully recovered from toxicity resulting from past
             treatment(s) that affects the assessments in this study at the enrollment.

          -  The subject with the following conditions during screening assessment.

               1. proteinuria CTC grade &gt; 1 as measured by urinalysis and 24 hour urine collection

               2. diastolic blood pressure (BP) &gt; 95 mmHg; or systolic blood pressure (BP) &gt; 150
                  mmHg

               3. a history of or currently exhibits clinically significant cancer related events
                  of bleeding

               4. LV Ejection Fraction &lt; 50%

               5. received a cumulative dose of Anthracycline &gt; 360 mg/m2 for treatment of cancer

               6. receiving therapeutic anticoagulation therapy

               7. having fractures except for chronic bone lesion due to bone metastases

          -  The subject exhibits evidence of other clinically significant uncontrolled
             condition(s).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susumu Matsuki, BS</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Japan Co.,Ltd</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <results_reference>
    <citation>Asahina H, Tamura Y, Nokihara H, Yamamoto N, Seki Y, Shibata T, Goto Y, Tanioka M, Yamada Y, Coates A, Chiu YL, Li X, Pradhan R, Ansell PJ, McKeegan EM, McKee MD, Carlson DM, Tamura T. An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemother Pharmacol. 2012 Jun;69(6):1477-86. doi: 10.1007/s00280-012-1846-6. Epub 2012 Mar 2.</citation>
    <PMID>22382879</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2008</study_first_submitted>
  <study_first_submitted_qc>July 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2008</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

